Alexion to Present at the 14th Annual Citi Biotech Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Stifel Reiterates Hold Rating on Alexion Pharmaceuticals (ALXN)
August 30, 2019 12:14 PM EDTStifel analyst Paul Matteis reiterated a Hold rating and {REMOVEPT} price target on Alexion Pharmaceuticals (NASDAQ: ALXN)
The analyst comments "While the implications of a theoretical Soliris biosimilar launch (assuming ALXN converts) remain debatable, we expect the IPR institution decision this morning... More
Citi Is Buyer on Weakness in Alexion Pharmaceuticals (ALXN), Sees Fair Value around $131-$133
August 30, 2019 12:00 PM EDTCiti analyst Mohit Bansal reiterated a Buy rating and $150.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN).
Analyst is buyer on weakness.Sees FV around $131 to $133 per share.Says while weakness is justified, there is still value in the... More


